Compare Crispr Therapeutics AG (CRSP) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Enovix Corporation — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Enovix Corporation trades at $5.09 (market cap $1.10B). The key difference: Crispr Therapeutics AG is far larger — about 4.5× Enovix Corporation's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| CRSP | ENVX | |
|---|---|---|
Market Cap | $4.97B | $1.10B |
Sector | Health | Technology |
52-Week High | $76.78 | $15.93 |
52-Week Low | $44.34 | $4.84 |
Enterprise Value | $3.32B | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ENVX trades at $4.95, down 4.81% with bearish technical signals despite recent earnings beats. The company shows negative profitability with -499.64% net margin and -$156.74M net loss for 2025, though revenue grew to $31.82M. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in battery technology commercialization.
While analyst consensus remains bullish with a $12.75 price target, significant execution risks persist given negative cash flows and high valuation multiples. The stock presents high-risk speculation on Enovix's ability to scale production and achieve profitability in the competitive battery technology market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
